Why the study?
Intracoronary nicorandil is commonly used to treat coronary microvascular dysfunction during PPCI, but cardiac arrest caused by nicorandil had not been previously reported.
Does intracoronary nicorandil cause cardiac arrest in patients undergoing primary percutaneous coronary intervention for STEMI?
Does intracoronary nicorandil cause cardiac arrest in patients undergoing primary percutaneous coronary intervention for STEMI?
This is the first reported case of cardiac arrest induced by intracoronary nicorandil during primary PCI, highlighting a severe potential side effect of a commonly used medication for slow flow/no-reflow.
Alerts to cardiac arrest risk with intracoronary nicorandil during PPCI; leaves open need for safety data before broader use.
RATIONALE: Primary percutaneous coronary intervention (PPCI) is the most effective therapy for patients with an acute ST-segment elevation myocardial infarction (STEMI). However, up to half of STEMI patients suffer from coronary microvascular dysfunction, presenting as the slow flow or no-reflow phenomenon. PATIENTS CONCERNS: A 78-year-old man was admitted to the chest pain center with sudden chest pain and tightness for about an hour. DIAGNOSES: Electrocardiography demonstrated ST-segment elevation in leads II, III, aVF, and third-degree atrioventricular block. Coronary angiography showed acute total occlusion in the distal right coronary artery (RCA). INTERVENTIONS: PPCI was performed on the patient. After thrombus aspiration, a stent was placed in the distal RCA. As coronary angiography showed TIMI grade 2 flow in RCA, 6 mg nicorandil was intracoronary administrated in twice. Immediately, cardiac arrest occurred and cardiopulmonary resuscitation (CPR) was performed. OUTCOMES: The patient survived and had a good outcome during follow-up for >6 months. LESSONS: Up to now, there has been no case report of cardiac arrest caused by nicorandil. Although intracoronary nicorandil is one of the most commonly used methods to improve coronary flow, much more attention should be paid to side effects of nicorandil.
No takes yet. Share an insight, caveat, or question.
Wei et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: